Merck & Company Says Study Meets Primary Endpoint

Merck & Company Says Study Meets Primary Endpoint

Merck’s said its study of anacetrapib met its primary endpoint, significantly reducing major coronary events compared with placebo. The company has not decided whether it will file the product, anacetrapib has been viewed as effectively a call option for the story, and as a result JPMorgan said the news is an “incremental positive” for Merck. While CETPs, which lowered LDL and raise HDL, target a large potential market, the data […]

Read More ˃
Concordia International Hires Perella Weinberg Partners

Concordia International Hires Perella Weinberg Partners

Concordia International an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, said Wednesday it has engaged Perella Weinberg Partners LP to provide financial advisory services to help with the development of its long-term growth strategy. Parella Weinberg Partners’ services “may include, but are not limited to, helping the company explore and evaluate potential transactional alternatives, including initiatives to optimize its capital structure,” the company said in a […]

Read More ˃
Sorrento Therapeutics Higher

Sorrento Therapeutics Higher

Sorrento Therapeutics rose more than 12% after the company said its lead investigational product, ZTlido has demonstrated superior adhesion versus the EU reference product Versatis during a recently completed comparative adhesion performance study. These data complement a previous clinical adhesion study performed to support the new drug application (NDA) submission for ZTlido in the US, where greater than 90% of the subjects demonstrated greater than 90% adhesion over the 12-hour […]

Read More ˃
Allergan to Unveil New Data

Allergan to Unveil New Data

Allergan plc said pre-market Wednesday that new data on its chronic migraine treatment Botox will be featured in eight presentations at the annual meeting of the American Headache Society taking place in Boston from June 8 to 11. The presentations consist of two oral presentations, three poster presentations on chronic migraine disease awareness and three posters containing long-term efficacy data on Botox as a treatment of chronic migraine from the […]

Read More ˃
Donaldson Company Fiscal Q3 Beats Estimates

Donaldson Company Fiscal Q3 Beats Estimates

Donaldson Company reported fiscal Q3 adjusted earnings of $0.45 per share, versus $0.43 last year. This beat the Capital IQ estimate by a penny. Revenue for the quarter, which ended April 30, was $608.2 million, versus $571.3 million last year. This topped the $580.4 million Capital IQ estimate. Donaldson said it now expects full-year 2017 adjusted EPS between $1.67 and $1.71, compared with prior guidance of $1.60 to $1.68 and […]

Read More ˃